The Truth about Interventions In Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Truth about Interventions In Aseptic Processing
Aseptic processing has advanced over the past several decades, yet the pharmaceutical industry is still accepting of its limitations, particularly as it relates to human intervention as a source of contamination. The authors explain the importance of further diminishing the role of operators in aseptic processing and the approaches and technologies needed to achieve that goal.


Pharmaceutical Technology


Conclusion

An obvious but simple truth and perhaps the most critical truth of all is that the absence of microorganisms in any aseptic environment can never be proven. In isolators, we rarely detect microorganisms, but in cleanrooms, we rarely go more than a few days without recovering organisms despite sampling methods that have a rather poor limit of detection. The most painful truth of all, therefore, is that manned cleanrooms were never sterile, are not sterile now, and never will be sterile. We suspect it is rather obvious what that means about sterile products made in these facilities. Make no mistake; we think that by and large products made in the best manned cleanrooms are safe, maybe even safe enough. Cleanrooms that are less than the best, however, are a very different matter altogether. One last truth: There are better technologies available for aseptic processing than conventional manned cleanrooms, and we should be using those technologies. Unless we do, the truth is we will never reach the goal of having operators playing a diminishing role in aseptic operations.

James P. Agalloco* is the president of Agalloco & Associates, PO Box 899, Belle Mead, NJ 08502, tel. 908.874.7558,
He also is a member of Pharmaceutical Technology's Editorial Advisory Board. James E. Akers is the president of Akers Kennedy & Associates, PO Box 22562, Kansas City, MO 64113,

*To whom all correspondence should be addressed.

Key words: aseptic processing, cleanrooms, isolators, operators, RABS, sterile.

References

1. PDA, "Current Practices in the Validation of Aseptic Processing–2001," PDA Technical Report 36, PDA J. Pharm. Sci. Technol. 56 (3) (2002).

2. ISPE, "Restricted Access Barrier Systems (RABS) for Aseptic Processing Definition," Aug. 16, 2005.

3. PDA, "Process Simulation Testing for Sterile Bulk Pharmaceutical Chemicals," Technical Report 28, PDA J. Pharm. Sci. Technol. 60 (s-2) suppl. (2006).

4. PDA, "Design and Validation of Isolator Systems for the Manufacturing and Testing of Health Care Products," Technical Report 34, PDA J. Pharm. Sci. Technol. 55 (5) suppl. (2001).

5. H. Avallone, "Current Regulatory Issues Regarding Parenteral Inspections," J. Parenteral Sci. Technol. 43 (1), 3–7 (1989).

6. V. Sigwarth, A. Gessler, and A. Stark, "Relevance of Physical Glove Integrity Testing to Microbial Contamination of Isolator Systems," presented at ISPE meeting, Prague, Czech Republic, 2005.

7. J. Agalloco and J. Akers, "Simplified Risk Analysis for Aseptic Processing: The Akers-Agalloco Method," Pharm. Technol. 30 (7), 60–76 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here